Cargando…
The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy
Large amounts of dead and dying cells are produced during cancer therapy and allograft rejection. Depending on the death pathway and stimuli involved, dying cells exhibit diverse features, resulting in defined physiological consequences for the host. It is not fully understood how dying and dead cel...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227513/ https://www.ncbi.nlm.nih.gov/pubmed/25426116 http://dx.doi.org/10.3389/fimmu.2014.00560 |
_version_ | 1782343820900302848 |
---|---|
author | Chaurio, Ricardo A. Muñoz, Luis E. Maueröder, Christian Janko, Christina Harrer, Thomas Fürnrohr, Barbara G. Niederweis, Michael Bilyy, Rostyslav Schett, Georg Herrmann, Martin Berens, Christian |
author_facet | Chaurio, Ricardo A. Muñoz, Luis E. Maueröder, Christian Janko, Christina Harrer, Thomas Fürnrohr, Barbara G. Niederweis, Michael Bilyy, Rostyslav Schett, Georg Herrmann, Martin Berens, Christian |
author_sort | Chaurio, Ricardo A. |
collection | PubMed |
description | Large amounts of dead and dying cells are produced during cancer therapy and allograft rejection. Depending on the death pathway and stimuli involved, dying cells exhibit diverse features, resulting in defined physiological consequences for the host. It is not fully understood how dying and dead cells modulate the immune response of the host. To address this problem, different death stimuli were studied in B16F10 melanoma cells by regulated inducible transgene expression of the pro-apoptotic active forms of caspase-3 (revCasp-3), Bid (tBid), and the Mycobacterium tuberculosis-necrosis inducing toxin (CpnT(CTD)). The immune outcome elicited for each death stimulus was assessed by evaluating the allograft rejection of melanoma tumors implanted subcutaneously in BALB/c mice immunized with dying cells. Expression of all proteins efficiently killed cells in vitro (>90%) and displayed distinctive morphological and physiological features as assessed by multiparametric flow cytometry analysis. BALB/c mice immunized with allogeneic dying melanoma cells expressing revCasp-3 or CpnT(CTD) showed strong rejection of the allogeneic challenge. In contrast, mice immunized with cells dying either after expression of tBid or irradiation with UVB did not, suggesting an immunologically silent cell death. Surprisingly, immunogenic cell death induced by expression of revCasp-3 or CpnT(CTD) correlated with elevated intracellular reactive oxygen species (ROS) levels at the time point of immunization. Conversely, early mitochondrial dysfunction induced by tBid expression or UVB irradiation accounted for the absence of intracellular ROS accumulation at the time point of immunization. Although ROS inhibition in vitro was not sufficient to abrogate the immunogenicity in our allo-immunization model, we suggest that the point of ROS generation and its intracellular accumulation may be an important factor for its role as damage associated molecular pattern in the development of allogeneic responses. |
format | Online Article Text |
id | pubmed-4227513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-42275132014-11-25 The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy Chaurio, Ricardo A. Muñoz, Luis E. Maueröder, Christian Janko, Christina Harrer, Thomas Fürnrohr, Barbara G. Niederweis, Michael Bilyy, Rostyslav Schett, Georg Herrmann, Martin Berens, Christian Front Immunol Immunology Large amounts of dead and dying cells are produced during cancer therapy and allograft rejection. Depending on the death pathway and stimuli involved, dying cells exhibit diverse features, resulting in defined physiological consequences for the host. It is not fully understood how dying and dead cells modulate the immune response of the host. To address this problem, different death stimuli were studied in B16F10 melanoma cells by regulated inducible transgene expression of the pro-apoptotic active forms of caspase-3 (revCasp-3), Bid (tBid), and the Mycobacterium tuberculosis-necrosis inducing toxin (CpnT(CTD)). The immune outcome elicited for each death stimulus was assessed by evaluating the allograft rejection of melanoma tumors implanted subcutaneously in BALB/c mice immunized with dying cells. Expression of all proteins efficiently killed cells in vitro (>90%) and displayed distinctive morphological and physiological features as assessed by multiparametric flow cytometry analysis. BALB/c mice immunized with allogeneic dying melanoma cells expressing revCasp-3 or CpnT(CTD) showed strong rejection of the allogeneic challenge. In contrast, mice immunized with cells dying either after expression of tBid or irradiation with UVB did not, suggesting an immunologically silent cell death. Surprisingly, immunogenic cell death induced by expression of revCasp-3 or CpnT(CTD) correlated with elevated intracellular reactive oxygen species (ROS) levels at the time point of immunization. Conversely, early mitochondrial dysfunction induced by tBid expression or UVB irradiation accounted for the absence of intracellular ROS accumulation at the time point of immunization. Although ROS inhibition in vitro was not sufficient to abrogate the immunogenicity in our allo-immunization model, we suggest that the point of ROS generation and its intracellular accumulation may be an important factor for its role as damage associated molecular pattern in the development of allogeneic responses. Frontiers Media S.A. 2014-11-11 /pmc/articles/PMC4227513/ /pubmed/25426116 http://dx.doi.org/10.3389/fimmu.2014.00560 Text en Copyright © 2014 Chaurio, Muñoz, Maueröder, Janko, Harrer, Fürnrohr, Niederweis, Bilyy, Schett, Herrmann and Berens. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Chaurio, Ricardo A. Muñoz, Luis E. Maueröder, Christian Janko, Christina Harrer, Thomas Fürnrohr, Barbara G. Niederweis, Michael Bilyy, Rostyslav Schett, Georg Herrmann, Martin Berens, Christian The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy |
title | The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy |
title_full | The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy |
title_fullStr | The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy |
title_full_unstemmed | The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy |
title_short | The Progression of Cell Death Affects the Rejection of Allogeneic Tumors in Immune-Competent Mice – Implications for Cancer Therapy |
title_sort | progression of cell death affects the rejection of allogeneic tumors in immune-competent mice – implications for cancer therapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227513/ https://www.ncbi.nlm.nih.gov/pubmed/25426116 http://dx.doi.org/10.3389/fimmu.2014.00560 |
work_keys_str_mv | AT chaurioricardoa theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT munozluise theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT maueroderchristian theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT jankochristina theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT harrerthomas theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT furnrohrbarbarag theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT niederweismichael theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT bilyyrostyslav theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT schettgeorg theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT herrmannmartin theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT berenschristian theprogressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT chaurioricardoa progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT munozluise progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT maueroderchristian progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT jankochristina progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT harrerthomas progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT furnrohrbarbarag progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT niederweismichael progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT bilyyrostyslav progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT schettgeorg progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT herrmannmartin progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy AT berenschristian progressionofcelldeathaffectstherejectionofallogeneictumorsinimmunecompetentmiceimplicationsforcancertherapy |